Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers

Jennifer A. Westwood, Geoffrey M. Matthews, Jake Shortt, David Faulkner, Hollie J. Pegram, Connie P M Duong, Marta Chesi, Peter Leif Bergsagel, Leslie L. Sharp, Richard D. Huhn, Phillip K. Darcy, Ricky W. Johnstone, Michael H. Kershaw

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine if it would be successful in a mouse model of multiple myeloma. Firstly, we tested a transplantable model of disease in which multiple myeloma cells derived from Vk*MYC mice were injected intravenously. A minor proportion of anti-CD137 and BiMab treated mice experienced prolongation of life beyond 250 days. Then we tested the therapy in a spontaneously occurring multiple myeloma model, in Vk*MYC transgenic mice. The majority of mice treated survived longer than control mice, although statistical significance was not demonstrated.

Original languageEnglish (US)
Pages (from-to)948-954
Number of pages7
JournalLeukemia Research
Volume38
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Anti-Idiotypic Antibodies
Neoplasms
Multiple Myeloma
Therapeutics
Lymphoma
Life Support Care
Antigen Presentation
Colonic Neoplasms
Transgenic Mice
Monoclonal Antibodies
Research Personnel
T-Lymphocytes

Keywords

  • Anti-CD137
  • Anti-CD40
  • Eμ-Myc
  • Lymphoma
  • Multiple myeloma
  • myc

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Westwood, J. A., Matthews, G. M., Shortt, J., Faulkner, D., Pegram, H. J., Duong, C. P. M., ... Kershaw, M. H. (2014). Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research, 38(8), 948-954. https://doi.org/10.1016/j.leukres.2014.05.010

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. / Westwood, Jennifer A.; Matthews, Geoffrey M.; Shortt, Jake; Faulkner, David; Pegram, Hollie J.; Duong, Connie P M; Chesi, Marta; Bergsagel, Peter Leif; Sharp, Leslie L.; Huhn, Richard D.; Darcy, Phillip K.; Johnstone, Ricky W.; Kershaw, Michael H.

In: Leukemia Research, Vol. 38, No. 8, 2014, p. 948-954.

Research output: Contribution to journalArticle

Westwood, JA, Matthews, GM, Shortt, J, Faulkner, D, Pegram, HJ, Duong, CPM, Chesi, M, Bergsagel, PL, Sharp, LL, Huhn, RD, Darcy, PK, Johnstone, RW & Kershaw, MH 2014, 'Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers', Leukemia Research, vol. 38, no. 8, pp. 948-954. https://doi.org/10.1016/j.leukres.2014.05.010
Westwood, Jennifer A. ; Matthews, Geoffrey M. ; Shortt, Jake ; Faulkner, David ; Pegram, Hollie J. ; Duong, Connie P M ; Chesi, Marta ; Bergsagel, Peter Leif ; Sharp, Leslie L. ; Huhn, Richard D. ; Darcy, Phillip K. ; Johnstone, Ricky W. ; Kershaw, Michael H. / Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. In: Leukemia Research. 2014 ; Vol. 38, No. 8. pp. 948-954.
@article{50e400360d464bd084d15544e814f174,
title = "Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers",
abstract = "In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine if it would be successful in a mouse model of multiple myeloma. Firstly, we tested a transplantable model of disease in which multiple myeloma cells derived from Vk*MYC mice were injected intravenously. A minor proportion of anti-CD137 and BiMab treated mice experienced prolongation of life beyond 250 days. Then we tested the therapy in a spontaneously occurring multiple myeloma model, in Vk*MYC transgenic mice. The majority of mice treated survived longer than control mice, although statistical significance was not demonstrated.",
keywords = "Anti-CD137, Anti-CD40, Eμ-Myc, Lymphoma, Multiple myeloma, myc",
author = "Westwood, {Jennifer A.} and Matthews, {Geoffrey M.} and Jake Shortt and David Faulkner and Pegram, {Hollie J.} and Duong, {Connie P M} and Marta Chesi and Bergsagel, {Peter Leif} and Sharp, {Leslie L.} and Huhn, {Richard D.} and Darcy, {Phillip K.} and Johnstone, {Ricky W.} and Kershaw, {Michael H.}",
year = "2014",
doi = "10.1016/j.leukres.2014.05.010",
language = "English (US)",
volume = "38",
pages = "948--954",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers

AU - Westwood, Jennifer A.

AU - Matthews, Geoffrey M.

AU - Shortt, Jake

AU - Faulkner, David

AU - Pegram, Hollie J.

AU - Duong, Connie P M

AU - Chesi, Marta

AU - Bergsagel, Peter Leif

AU - Sharp, Leslie L.

AU - Huhn, Richard D.

AU - Darcy, Phillip K.

AU - Johnstone, Ricky W.

AU - Kershaw, Michael H.

PY - 2014

Y1 - 2014

N2 - In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine if it would be successful in a mouse model of multiple myeloma. Firstly, we tested a transplantable model of disease in which multiple myeloma cells derived from Vk*MYC mice were injected intravenously. A minor proportion of anti-CD137 and BiMab treated mice experienced prolongation of life beyond 250 days. Then we tested the therapy in a spontaneously occurring multiple myeloma model, in Vk*MYC transgenic mice. The majority of mice treated survived longer than control mice, although statistical significance was not demonstrated.

AB - In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine if it would be successful in a mouse model of multiple myeloma. Firstly, we tested a transplantable model of disease in which multiple myeloma cells derived from Vk*MYC mice were injected intravenously. A minor proportion of anti-CD137 and BiMab treated mice experienced prolongation of life beyond 250 days. Then we tested the therapy in a spontaneously occurring multiple myeloma model, in Vk*MYC transgenic mice. The majority of mice treated survived longer than control mice, although statistical significance was not demonstrated.

KW - Anti-CD137

KW - Anti-CD40

KW - Eμ-Myc

KW - Lymphoma

KW - Multiple myeloma

KW - myc

UR - http://www.scopus.com/inward/record.url?scp=84904536509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904536509&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.05.010

DO - 10.1016/j.leukres.2014.05.010

M3 - Article

VL - 38

SP - 948

EP - 954

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -